法律意见书 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2024 年年度股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2024 年年度股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）》《上市公司股东会规则》等相关法律、法规、规范性文件 及《哈尔滨三联药业股份有限公司章程》（以下简称"《公司章程》"）的规定， 对本次股东大会进行见证并出具法律意见。 1 法律意见书 即其已提供了本所律师认为作为出具本法律意见书所必需的材料，所提供的原始 材料、副本、复印件等材料、口头证言均符合真实、准确、完整的要求，有关副 本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 等法律、法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的议 案内 ...

Market Overview - The market experienced a volume contraction with the ChiNext index dropping nearly 2% by the end of the day. The synthetic biology concept stocks surged, with companies like Chuaning Biological, Jieya Co., and Meinong Biological hitting the daily limit. The shipping sector saw a rise and subsequent fall, with Ningbo Shipping, Ningbo Ocean, and Lianyungang achieving three consecutive limits. Consumer stocks in food, apparel, and beauty care were active, with Xiwang Food, Lafang Cosmetics, and Fengzhu Textile also hitting the daily limit. Conversely, the military industry faced adjustments, with Tianjian Technology nearing a limit down, and computing power concept stocks weakened, with Hongjing Technology dropping nearly 10%. Overall, over 3,800 stocks in the Shanghai and Shenzhen markets declined, with a total transaction volume of 1.19 trillion [1]. Hot Topics Health Products - Kolun Pharmaceutical's advertisement for ergothioneine capsules has sparked significant discussion, with Chairman Liu Gexin personally endorsing the product. Ergothioneine is a natural small molecule derived from histidine thiourea, found in microbial cells and plants. It cannot be synthesized by the human body and must be obtained through diet, with mushrooms being a key source. Sales of oral beauty products containing ergothioneine on a major e-commerce platform surged by 60 times year-on-year in the first half of 2024 [4][5]. Shipping - The shipping sector remained active, with Ningbo Ocean and Lianyungang achieving three consecutive limits. Following trade negotiations between China and the U.S., container shipping bookings from China to the U.S. surged nearly 300%, with the average booking volume for 20-foot standard containers skyrocketing to 21,530, up from 5,709 a week prior. Goldman Sachs anticipates a significant increase in Chinese exports over the next 90 days due to a tariff suspension [6][8]. Consumer Sector - The consumer sector was lively, with stocks like Marubi, Dengkang Dental, and Baiyang hitting the daily limit. The Tmall 618 promotion commenced, with the first hour's GMV for popular beauty products increasing over 10% year-on-year. Additionally, the price of tilapia has risen to 4.5 yuan per pound, with China being a major producer and exporter of tilapia, producing over 1.6 million tons annually, with about a quarter exported to the U.S. [9][10]. Stock Performance - Notable stocks in the health products sector include: - Jiaoda Aongli (600530.SS) with a price of 7.50, up 9.97%, and a market cap of 5.812 billion - Lafang Cosmetics with a price of 21.97, up 10.02%, and a market cap of 4.948 billion - Chuaning Biological with a price of 14.02, up 20.03%, and a market cap of 8.635 billion [5][10]. - In the shipping sector: - Ningbo Ocean (601022.SS) at 11.12, up 9.99%, with a market cap of 2.765 billion - Lianyungang (601008.SS) at 6.77, up 10.08%, with a market cap of 8.399 billion [7][10]. - In the consumer sector: - Zhejiang Yongqiang (002489.SZ) at 4.07, up 10.00%, with a market cap of 7.786 billion - Marubi (603983.SS) at 52.53, up 10.01%, with a market cap of 21.065 billion [10].

证券代码： 002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活 | □特定对象调研 □ 分析师会议 | | □ 现场参观 | | --- | --- | --- | --- | | 动类别 | □ 媒体采访 | √ 业绩说明会 | □ 其他 | | | □ 新闻发布会 | □ 路演活动 | | | 参与单位名称 | 关于参加黑龙江辖区上市公司 年投资者网上集体接待日活动暨业 | 2025 | | | 及人员姓名 | 绩说明会，投资者网上提问。 | | | | 时间 | 2025 年 5 月 14 日（周三）下午 14:00~16:30 | | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 公司接待人员 | 1、董事、副总裁兼董事会秘书梁延飞先生 | | | | 姓名 | 2、财务总监赵志成先生 | | | | | 1、公司医美产业发展如何？有没有特色优势产品？ | | | | | 尊敬的投资者您好：公司大健康板块目前包括化妆品、医用敷料、 | | | | | "好好"系列纳米乳化饮 ...

证券之星消息，5月9日哈三联公开信息显示，哈尔滨三联药业股份有限公司，董事长秦剑飞、副总经理 梁延飞、财务总监赵志成因未及时披露公司重大事件,未依法履行其他职责被黑龙江证监局出具警示 函。 采取出具警示函的行政监管措施,并记入证券期货市场诚信档案 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 经查,哈尔滨三联药业股份有限公司(以下简称哈三联或公司,统一社会信用代码:91230100607168790X)存 在以下问题:2022年7月至2023年7月,哈三联以支付预付款的形式向哈尔滨泰盛昌包装印刷有限公司(以下 简称泰盛昌)累计支付2,250万元,泰盛昌未实际交货并退回相关款项;2023年1月至2024年3月,哈三联以支 付预付款的形式向中孚药业股份有限公司(以下简称中孚药业)累计支付2,200万元,中孚药业未实际交货, 退回相关款项并支付利息。前述事项构成哈三联对外财务资助,公司未按规定履行相应的审议程序和信 息披露义务,上述情形违反了《上市公司信息披露管理办法》(证监会令第182号)第三条第一款以及《深 圳证券交易所股票上市规则 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

证券代码：002900 证券简称：哈三联 公告编号：2025-026 哈尔滨三联药业股份有限公司 关于参加黑龙江辖区上市公司 2025 年投资者网上集体接待日活 动暨业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会与深圳市全景网络有限公司联合举办 的"2025 年黑龙江辖区上市公司投资者集体接待日活动"，现将相关事项公告如 下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2025 年 5 月 14 日（周三）14:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2025 年 5 月 9 ...

氯化钾氯化钠注射液用于： （1）治疗各种原因引起的低钾血症，如进食不足、呕吐、严重腹泻、应用 排钾性利尿药、低钾性家族周期性麻痹、长期应用糖皮质激素和补充高渗葡萄糖 后引起的低钾血症等。 证券代码：002900 证券简称：哈三联 公告编号：2025-027 哈尔滨三联药业股份有限公司 关于公司药品通过一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的药品补充申请批准通知书，公司药品氯化钾氯化钠注射液通过 仿制药质量和疗效一致性评价（以下简称"一致性评价"）。具体情况如下： | 药品名称 | 规格 | | 注册分类 | 上市许可持有人 | 审批结论 | | --- | --- | --- | --- | --- | --- | | 氯化钾氯化 | 100ml：氯化钾 与氯化钠 | 0.3g 0.9g 0.75g | 化学药品 | 哈尔滨三联药业 | 经审查，本品通过仿制药 | | | 250ml：氯化钾 | | | | | | 钠注射液 | 与氯化钠 | 2.2 ...

Group 1 - The company Harsanlian (002900) announced that its drug Potassium Chloride and Sodium Chloride Injection has passed the consistency evaluation of generic drug quality and efficacy [1] - This drug is used to treat hypokalemia caused by various reasons, prevent hypokalemia, and address arrhythmias caused by digitalis poisoning [1] - The company is the first in China to pass the consistency evaluation for all three specifications of Potassium Chloride and Sodium Chloride Injection, which will enhance the product's technical level and market competitiveness [1]

Core Insights - The company reported a revenue of 1.132 billion yuan in 2024, a decrease of 4.58% year-on-year, and a net profit attributable to shareholders of 58.68 million yuan, down 20.35% year-on-year [1][2] - The company's net profit excluding non-recurring items saw a significant increase of 73.85%, reaching 53.23 million yuan [1][2] - Basic earnings per share decreased to 0.19 yuan, down 20.83% from the previous year [2] Financial Performance - Revenue for 2024 was 1,132,476,522.09 yuan, compared to 1,186,786,001.40 yuan in 2023, reflecting a decline of 4.58% [2] - Net profit attributable to shareholders was 58,675,175.44 yuan, down from 73,663,110.90 yuan, a decrease of 20.35% [2] - The net profit after excluding non-recurring items was 53,233,408.45 yuan, a substantial increase from 30,619,980.53 yuan, marking a growth of 73.85% [2] - Operating cash flow was 30,687,788.46 yuan, down 14.02% from the previous year [2] - Total assets at the end of 2024 were 3.80 billion yuan, a 10.38% increase from 3.44 billion yuan in 2023 [2] Business Segments - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, accounting for 87.34% of total revenue, facing pressure from centralized procurement policies [3] - The veterinary medicine segment saw a dramatic increase in revenue to 75.20 million yuan, up 740.79%, driven by the launch of the Lingbao veterinary project and increased demand in the animal health market [3] - The functional food sector grew by 170%, and the cosmetics sector grew by 100%, emerging as new growth areas for the company [3] Research and Development - The company invested 1.22 billion yuan in R&D in 2024, representing 10.78% of total revenue, with a capitalization rate of 13.83% [3] - Ongoing projects include the development of new drugs such as Nimodipine tablets and Asenapine sublingual tablets, with three new patents granted, bringing the total to 137 patents focused on the nervous and cardiovascular systems [3]

5月6日，哈尔滨三联药业股份有限公司（以下简称"哈三联"）发布公告称，因近两年通过预付款形式向 关联方违规提供财务资助4450万元且未履行信披义务，公司连同董事长秦剑飞、财务总监赵志成、董事 会秘书梁延飞被黑龙江证监局出具警示函。 信披违规收警示函 根据《警示函》，2022年7月至2023年7月，哈三联以支付预付款的形式向哈尔滨泰盛昌包装印刷有限公 司（以下简称"泰盛昌"）累计支付2250万元，泰盛昌未实际交货并退回相关款项；2023年1月至2024年3 月，哈三联以支付预付款的形式向中孚药业股份有限公司（以下简称"中孚药业"）累计支付2200万元， 中孚药业未实际交货，退回相关款项并支付利息。 黑龙江证监局认为，前述事项构成哈三联对外财务资助，公司未按规定履行相应的审议程序和信息披露 义务，违反了相关规定。公司董事长兼总经理、时任董事会秘书秦剑飞，财务总监赵志成，董事会秘书 梁延飞未按照规定履行勤勉尽责义务，对公司上述违规行为负有主要责任。 按照相关规定，黑龙江证监局决定对哈三联、秦剑飞、赵志成、梁延飞分别采取出具警示函的行政监管 措施，并记入证券期货市场诚信档案，公司及有关责任人需提交书面报告。 哈三联表 ...